Literature DB >> 30393597

Osimertinib in first line setting: preventive or delayed T790M occurrence?

Hao Sun1, Yilong Wu2.   

Abstract

Entities:  

Year:  2018        PMID： 30393597      PMCID： PMC6193897          DOI： 10.21037/tlcr.2018.04.16

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Authors:  Dalia Ercan; Hwan Geun Choi; Cai-Hong Yun; Marzia Capelletti; Ting Xie; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2015-05-06       Impact factor: 12.531

2.  Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Suzanne Jenkins; James C-H Yang; Suresh S Ramalingam; Karen Yu; Sabina Patel; Susie Weston; Rachel Hodge; Mireille Cantarini; Pasi A Jänne; Tetsuya Mitsudomi; Glenwood D Goss
Journal:  J Thorac Oncol       Date:  2017-04-17       Impact factor: 15.609

3.  Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Camelia S Sima; Gregory J Riely; Juliann Chmielecki; Mark G Kris; William Pao; Marc Ladanyi; Vincent A Miller
Journal:  Clin Cancer Res       Date:  2010-12-06       Impact factor: 12.531

4.  Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.

Authors:  Jeng-Sen Tseng; Tsung-Ying Yang; Chi-Ren Tsai; Kun-Chieh Chen; Kuo-Hsuan Hsu; Meen-Hsin Tsai; Sung-Liang Yu; Kang-Yi Su; Jeremy J W Chen; Gee-Chen Chang
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

5.  ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.

Authors:  Martin Reck; Koichi Hagiwara; Baohui Han; Sergei Tjulandin; Christian Grohé; Takashi Yokoi; Alessandro Morabito; Silvia Novello; Edurne Arriola; Olivier Molinier; Rose McCormack; Marianne Ratcliffe; Nicola Normanno
Journal:  J Thorac Oncol       Date:  2016-07-25       Impact factor: 15.609

6.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

7.  Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Authors:  Hua-Jun Chen; Tony S Mok; Zhi-Hong Chen; Ai-Lin Guo; Xu-Chao Zhang; Jian Su; Yi-Long Wu
Journal:  Pathol Oncol Res       Date:  2009-04-21       Impact factor: 3.201

8.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Authors:  Suresh S Ramalingam; James C-H Yang; Chee Khoon Lee; Takayasu Kurata; Dong-Wan Kim; Thomas John; Naoyuki Nogami; Yuichiro Ohe; Helen Mann; Yuri Rukazenkov; Serban Ghiorghiu; Daniel Stetson; Aleksandra Markovets; J Carl Barrett; Kenneth S Thress; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2017-08-25       Impact factor: 44.544

9.  Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Authors:  D Zheng; X Ye; M Z Zhang; Y Sun; J Y Wang; J Ni; H P Zhang; L Zhang; J Luo; J Zhang; L Tang; B Su; G Chen; G Zhu; Y Gu; J F Xu
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.